Pharmaron Beijing Co (SZSE:300759) Debt-to-Equity : 0.65 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Debt-to-Equity?

Pharmaron Beijing Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥864 Mil. Pharmaron Beijing Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥7,388 Mil. Pharmaron Beijing Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥12,687 Mil. Pharmaron Beijing Co's debt to equity for the quarter that ended in Mar. 2024 was 0.65.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharmaron Beijing Co's Debt-to-Equity or its related term are showing as below:

SZSE:300759' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.53 Max: 1.25
Current: 0.65

During the past 10 years, the highest Debt-to-Equity Ratio of Pharmaron Beijing Co was 1.25. The lowest was 0.04. And the median was 0.53.

SZSE:300759's Debt-to-Equity is ranked worse than
79.78% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs SZSE:300759: 0.65

Pharmaron Beijing Co Debt-to-Equity Historical Data

The historical data trend for Pharmaron Beijing Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Debt-to-Equity Chart

Pharmaron Beijing Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.13

0.12

0.52

0.58

0.77

Pharmaron Beijing Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.56	0.53	0.52	0.77	0.65

Competitive Comparison of Pharmaron Beijing Co's Debt-to-Equity

For the Biotechnology subindustry, Pharmaron Beijing Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmaron Beijing Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Debt-to-Equity falls into.

Pharmaron Beijing Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharmaron Beijing Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(912.728	+	8784.863)	/	12556.797
	=	0.77

Pharmaron Beijing Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(864.465	+	7388.346)	/	12687.089
	=	0.65

Pharmaron Beijing Co (SZSE:300759) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pharmaron Beijing Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co (SZSE:300759) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

03759:Hong Kong 17Q1:Germany

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.

Executives

Lou Xiao Qiang	Directors, executives
Zheng Bei	Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines